Étude de l’action collective pour la différenciation des fromages de montagne dans la province de Trente, Alpes italiennes : une approche institutionnelle by Carine Pachoud

“…Le futur défi est alors de définir des arrangements institutionnels innovants permettant une différenciation durable des fromages.…”
Get full text

Is in situ simulation in emergency medicine safe? A scoping review by Guillaume Martel, Andrew Petrosoniak, Marcel Émond, Jennifer Truchot, Valérie Boucher, Éliane Raymond-Dufresne, Winny Li, Eva Jouhair

Get full text

Énergie non conventionnelle dans les Andes argentines : des territoires dépendants ou en transition ? by Sofia Villalba, Alejandra Ise, Luciana Clementi

“…Dans les processus de transition vers des systèmes énergétiques durables, des tensions sur les ressources naturelles et sur les territoires surgissent. …”
Get full text

Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States by Robert L. Coleman, Jamie Garside, Jean Hurteau, Joehl Nguyen, Monica Kobayashi

“…**Conclusions:** Patients with recurrent/advanced EC have a poor prognosis, highlighting the need for therapies with more durable benefits.…”
Get full text

La chambre syndicale ouvrière de la boucherie de Paris et la Bourse du travail de Paris (1886-1904) by Sylvain Leteux

“…Rolande Trempé affirme que « les Bourses du travail sont l’une des institutions qui ont le plus profondément et le plus durablement marqué le mouvement ouvrier français1 ». …”
Get full text

Emerging Strategies in Cartilage Repair and Joint Preservation by Mircea Adrian Focsa, Sorin Florescu, Armand Gogulescu

“…<i>Conclusions:</i> Combining regenerative techniques, including cell-based therapies, gene modifications, and advanced scaffolding, offers a promising pathway towards durable cartilage repair and joint preservation. Future research should focus on refining integrated therapeutic protocols, conducting long-term clinical evaluations, and embracing personalised treatment models driven by artificial intelligence and predictive algorithms.…”
Get full text

Harnessing AI for Enhanced Weather Prediction: A Focus on Rainfall by Hira Farman, Noman Islam, Noman Hasany

“…The abstract simply outlines the paper’s goal of constructing a durable rainfall prediction model based on a single classifier and the stacking method. …”
Get full text

Association between terminal pleural elastance and radiographic lung re-expansion after therapeutic thoracentesis in patients with symptomatic pleural effusion: a post-hoc analysis... by Fabien Maldonado, Michael Lester, Otis B Rickman, Lance J Roller, Sameer K Avasarala, James M Katsis, Robert J Lentz

“…Objectives Recurrent symptomatic effusions can be durably managed with pleurodesis or placement of indwelling pleural catheters. …”
Get full text

Interpretation of indoor air surveillance for respiratory infections: a prospective longitudinal observational study in a childcare settingResearch in context by Caspar Geenen, Steven Traets, Sarah Gorissen, Michiel Happaerts, Kurt Beuselinck, Lies Laenen, Jens Swinnen, Sien Ombelet, Joren Raymenants, Els Keyaerts, Emmanuel André

“…Using air CO2 concentrations to normalise such signals emerges as a promising approach. Funding: KU Leuven; DURABLE project, under the EU4Health Programme of the European Commission; Thermo Fisher Scientific.…”
Get full text

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results... by Emiel A. De Jaeghere, Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, Sandrine Aspeslagh, Alex De Caluwé, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen K. Van de Vijver, Frédéric Amant, Katrien Vandecasteele, Hannelore G. Denys

“…In conclusion, PRIMMO did not meet its primary objective in both cohorts; pembrolizumab, radiotherapy, and an IDC had modest but durable antitumor activity with acceptable but not negligible toxicity. …”
Get full text

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development by Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial

“…Despite the 41% response rate and durable responses observed with belantamab mafodotin in the Phase III confirmatory DREAMM-3 trial, the marketing license for belantamab mafodotin was later withdrawn from US and European markets when the trial did not meet its primary endpoint of superiority for progression-free survival compared with pomalidomide and dexamethasone. …”
Get full text

A New Risk Score Based on Lipid Indicators for Patients with Advanced Hepatocellular Carcinoma by Wei X, Guo Z, Zhang T, Liang J

“…In comparison to the best overall response (BOR), the score offered a more accurate evaluation of durable clinical benefit (DCB) (p < 0.001 in the training and validation group; p = 0.061 vs 0.001 in the training and validation group).Conclusion: A new score based on lipid markers is a useful tool for evaluating prognosis and distinguishing patients with DCB.Keywords: hepatocellular carcinoma, survival, prognosis, clinical response, risk score…”
Get full text

Peut-il y avoir une vie sobre sans travail sobre ? by Valérie Deruelle, Jean-Luc Metzger

“…Être sobre, impératif moral, consiste à limiter durablement les empreintes des activités humaines. Les réflexions de Judith Butler (2014) sur la vie bonne permettent de soutenir qu’une vie sobre ne peut idéalement se concevoir que par la délibération entre égaux, dans une société où chaque collectivité : d’une part, prend conscience de ses propres vulnérabilités (environnementales et sociales) ; d’autre part, reconnaît sa part de responsabilité dans la production de ces vulnérabilités ; et enfin, décide d’agir, de façon solidaire, pour les réduire. …”
Get full text

Fit accuracy and fracture resistance evaluation of advanced lithium disilicate crowns (in- vitro study) by Amro Khalil Fayed, Amir Shoukry Azer, Rewaa Gaber AboElhassan

“…Abstract Background Increasing demand for durable and aesthetically pleasing dental restorations, including laminates, inlays, onlays, and crowns, has led to advancements in all-ceramic systems, particularly with the development of advanced lithium disilicate materials. …”
Get full text

Bridging the Gap: Misaligned Perceptions of Urban Agriculture and Health Between Planning and Design Experts and Urban Farmers in Greater Lomé, Togo by Akuto Akpedze Konou, Kossiwa Zinsou-Klassou, Pablo Txomin Harpo De Roulet, Armel Firmin Kemajou Mbianda, Jérôme Chenal

Get full text

Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings by Maria Meira, Aurore Frey, Neila Chekkat, Magda Rybczynska, Zaki Sellam, Joon Seok Park, Francesca Smylie Gazzaniga, Alexia Parmentier, Marianne Le Gall, Gordon James Freeman, Dennis Lee Kasper, Arlene Helen Sharpe, Eric Rambeaux, Abdijapar Shamshiev

“…Therapeutic efficacy with durable responses has been demonstrated with several antibody drugs that block key immune checkpoint receptors, including PD-1, PD-L1, and CTLA-4. …”
Get full text

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders by Jeffrey A Meyerhardt, Sunil Kumar, Jessica A Zerillo, Aparna Parikh, James M Cleary, Scott Rodig, Benjamin Schlechter, Kimmie Ng, Stephanie K Dougan, Nora Horick, Glenn J Hanna, Andrew L Coveler, Anuj K Patel, Nadine J McCleary, Douglas A Rubinson, Jeffrey W Clark, Kent Mouw, Kathleen Pfaff, Thomas A Abrams, Matthew B Yurgelun, Eliezer M Van Allen, S Jennifer Wang, Leah H Biller, Harshabad Singh, Emma L Welsh, Brandon M Huffman, Lestat R Ali, Megan T Hoffman, Katherine A Metayer, Shayla Murray, Alexandra Bird, Jennifer A Chan, Wolfram Goessling, Jeffrey S Wisch, Brendan Reardon, Robert J Mayer, Catherine Del Vecchio Fitz, Charlotte Kuperwasser

“…Long-term responders had HPV-positive tumors, lacked liver metastases, and achieved a radiological complete response.Conclusions Pembrolizumab has durable efficacy in a rare subset of anal cancers. …”
Get full text

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial by Jelena Tica, Veronica V. Rezelj, Benoit Baron, Vitalija van Paassen, Javier Zaidman, Lee Fairlie, Gert Scheper, Mathieu Le Gars, Frank Struyf, Macaya Douoguih, Javier Ruiz-Guiñazú

“…Immune responses were durable for at least 6 months. Spike-binding antibody responses were comparable to those elicited in young adults aged 18–25 years who received a standard dose of Ad26.COV2.S in Phase 3 efficacy studies Reduced doses/dose volume of Ad26.COV2.S had an acceptable safety profile and elicited robust humoral immune responses in adolescents aged 12–17 years. …”
Get full text

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors by Alissa J. Cooper, MD, Andrea Arfe, PhD, Biagio Ricciuti, MD, Andréanne Gagné, MD, PhD, Lynette M. Sholl, MD, Alessandro Di Federico, MD, Mark M. Awad, MD, PhD, Mihaela Aldea, MD, PhD, Maria Rosa Ghigna, MD, Miruna Grecea, MD, Phoebe Clark, MS, Jamie E. Chaft, MD, Mark G. Kris, MD, Gregory J. Riely, MD, Charles M. Rudin, MD, PhD, Ibiayi Dagogo-Jack, MD, Mari Mino-Kenudson, MD, Lingzhi Hong, MD, PhD, Neda Kalhor, MD, Natalie Vokes, MD, Anita Bowman, MS, Soo-Ryum Yang, MD, Natasha Rekhtman, MD, PhD, Adam J. Schoenfeld, MD

“…Median progression-free survival from start of systemic therapy was 1.9 (95% CI: 1.4–14.5) months for chemo and immunotherapy, 1.6 (95% CI: 1.1–5.8) months for chemotherapy, and 3.3 (95% CI: 1.2–undefined) months for immunotherapy alone. Five patients had durable responses (≥2 y); all received immunotherapy as part of first-line regimens. …”
Get full text

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study by Pernelle Lavaud, Esma Saada-Bouzid, Renaud Sabatier, Olivia Le Saux, Thibault de la Motte Rouge, Anthony Gonçalves, Elodie Coquan, Jean-Sébastien Frenel, Marta Jiménez, Alice Hervieu, Laurent Mathiot, François Legrand, Claire Cropet, Edith Borcoman, Emmanuelle Charafe

“…The definitive discontinuation rate due to TRAEs was 16.1%.Conclusions Dual checkpoint blockade of PD-L1 and cytotoxic T-lymphocyte-associated antigen-4 combined with metronomic oral vinorelbine demonstrated meaningful and durable clinical activity in patients with previously treated advanced cervical cancer. …”
Get full text